Limits...
Calpain-2 expression is associated with response to platinum based chemotherapy, progression-free and overall survival in ovarian cancer.

Storr SJ, Safuan S, Woolston CM, Abdel-Fatah T, Deen S, Chan SY, Martin SG - J. Cell. Mol. Med. (2012)

Bottom Line: High levels of calpain-2 expression was significantly associated with platinum resistant tumours (P = 0.031).Furthermore, high expression of calpain-2 was significantly associated with progression-free (P = 0.049) and overall survival (P = 0.006) in this cohort.The association between calpain-2 expression and overall survival remained significant in multivariate analysis accounting for tumour grade, stage, optimal debulking and platinum sensitivity (hazard ratio = 2.174; 95% confidence interval = 1.144-4.130; P = 0.018).

View Article: PubMed Central - PubMed

Affiliation: Academic Oncology, University of Nottingham, School of Molecular Medical Sciences, Nottingham University Hospitals NHS Trust, Nottingham, UK.

Show MeSH

Related in: MedlinePlus

Kaplan–Meier analysis of progression-free survival showing the impact of calpastatin (A), calpain-1 (B) and calpain-2 (C) expression in cohort of 154 patients with significance determined using the log rank test. (A) low expression group has 37 observations and 15 events and high expression group has 78 observations and 46 events; (B) low expression group has 19 observations and 9 events and high expression group has 96 observations and 51 events; (C) low expression group has 40 observations and 17 events and high expression group has 75 observations and 46 events; where observations are the number of observations per group and events are those patients with progressive disease.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC3472029&req=5

fig02: Kaplan–Meier analysis of progression-free survival showing the impact of calpastatin (A), calpain-1 (B) and calpain-2 (C) expression in cohort of 154 patients with significance determined using the log rank test. (A) low expression group has 37 observations and 15 events and high expression group has 78 observations and 46 events; (B) low expression group has 19 observations and 9 events and high expression group has 96 observations and 51 events; (C) low expression group has 40 observations and 17 events and high expression group has 75 observations and 46 events; where observations are the number of observations per group and events are those patients with progressive disease.

Mentions: At the end of the follow-up period 85 patients had developed progressive-disease, with a median progression-free survival of 14 months. The expression of calpastatin and calpain-1 was not associated with overall or progression-free survival (Fig. 2A and B). However, high expression of calpain-2 was significantly associated with progression-free survival (P = 0.049) (Fig. 2C). In multivariate analysis, including grade, stage, optimal debulking and platinum sensitivity, calpain-2 expression was not an independent marker of progression-free survival (Table 2A). Tumour grade, stage, optimal debulking and platinum sensitivity were included in multivariate analysis following assessment using the Kaplan–Meier method and significance determined using the log-rank test with individual values of P = 0.004, P < 0.001, P < 0.001, and P < 0.001 respectively.


Calpain-2 expression is associated with response to platinum based chemotherapy, progression-free and overall survival in ovarian cancer.

Storr SJ, Safuan S, Woolston CM, Abdel-Fatah T, Deen S, Chan SY, Martin SG - J. Cell. Mol. Med. (2012)

Kaplan–Meier analysis of progression-free survival showing the impact of calpastatin (A), calpain-1 (B) and calpain-2 (C) expression in cohort of 154 patients with significance determined using the log rank test. (A) low expression group has 37 observations and 15 events and high expression group has 78 observations and 46 events; (B) low expression group has 19 observations and 9 events and high expression group has 96 observations and 51 events; (C) low expression group has 40 observations and 17 events and high expression group has 75 observations and 46 events; where observations are the number of observations per group and events are those patients with progressive disease.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC3472029&req=5

fig02: Kaplan–Meier analysis of progression-free survival showing the impact of calpastatin (A), calpain-1 (B) and calpain-2 (C) expression in cohort of 154 patients with significance determined using the log rank test. (A) low expression group has 37 observations and 15 events and high expression group has 78 observations and 46 events; (B) low expression group has 19 observations and 9 events and high expression group has 96 observations and 51 events; (C) low expression group has 40 observations and 17 events and high expression group has 75 observations and 46 events; where observations are the number of observations per group and events are those patients with progressive disease.
Mentions: At the end of the follow-up period 85 patients had developed progressive-disease, with a median progression-free survival of 14 months. The expression of calpastatin and calpain-1 was not associated with overall or progression-free survival (Fig. 2A and B). However, high expression of calpain-2 was significantly associated with progression-free survival (P = 0.049) (Fig. 2C). In multivariate analysis, including grade, stage, optimal debulking and platinum sensitivity, calpain-2 expression was not an independent marker of progression-free survival (Table 2A). Tumour grade, stage, optimal debulking and platinum sensitivity were included in multivariate analysis following assessment using the Kaplan–Meier method and significance determined using the log-rank test with individual values of P = 0.004, P < 0.001, P < 0.001, and P < 0.001 respectively.

Bottom Line: High levels of calpain-2 expression was significantly associated with platinum resistant tumours (P = 0.031).Furthermore, high expression of calpain-2 was significantly associated with progression-free (P = 0.049) and overall survival (P = 0.006) in this cohort.The association between calpain-2 expression and overall survival remained significant in multivariate analysis accounting for tumour grade, stage, optimal debulking and platinum sensitivity (hazard ratio = 2.174; 95% confidence interval = 1.144-4.130; P = 0.018).

View Article: PubMed Central - PubMed

Affiliation: Academic Oncology, University of Nottingham, School of Molecular Medical Sciences, Nottingham University Hospitals NHS Trust, Nottingham, UK.

Show MeSH
Related in: MedlinePlus